Acute Respiratory Distress Syndrome – Landscape & Forecast – Disease Landscape & Forecast
ARDS is an acute, severe lung injury that causes edema of the lung alveoli, leading to breathing abnormalities and insufficient oxygen levels in the circulating blood, which may be life-threatening owing to respiratory failure and/or multi-organ dysfunction. ARDS may be caused by sepsis, trauma, severe pneumonia, or inhalation of harmful substances and it is associated with a high mortality rate. No pharmacological therapy is specifically approved for ARDS and treatment is supportive, principally comprising nonpharmacological approaches (e.g., mechanical ventilation, oxygen supplementation). There is unmet need and thus commercial opportunity for effective pharmacotherapies that can reduce patients’ reliance on ventilation and the mortality associated with ARDS. There are no therapies in late stages of development for ARDS, and the pipeline comprises largely early- to mid-stage agents with diverse mechanisms of action (e.g., Apeptico/Mediolanum Farmaceutici’s sodium channel modulator solnatide).
QUESTIONS ANSWERED
- How will the size of the ARDS population change through 2026?
- What are the key drug targets emerging from basic and clinical research in ARDS? Which emerging therapies do ARDS experts consider most promising? How would new therapies influence management of ARDS patients?
- How are emerging ARDS drugs being evaluated, and which are likely to launch by 2026? What commercial impact will they have on the ARDS market?
PRODUCT DESCRIPTION
Niche & Rare Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Table of contents
- Acute Respiratory Distress Syndrome - Landscape & Forecast - Disease Landscape & Forecast
- Executive Summary
- Key Findings
- Regional Sales of Key Therapies to Treat Acute Respiratory Distress Syndrome: 2026
- SWOT Analysis
- Actionable Recommendations in Acute Respiratory Distress Syndrome, According to Intensive Care Specialists
- Key Findings
- Commercial Outlook
- Key Findings
- Expert Insight
- Drivers and Constraints
- What Factors Are Driving Sales in Acute Respiratory Distress Syndrome?
- What Factors Are Constraining Sales in Acute Respiratory Distress Syndrome
- Drug-Class-Specific Trends
- Sodium Channel Activators
- Key Findings
- Forecast
- Sales of Key Therapies in Acute Respiratory Distress Syndrome
- Epidemiology Overview
- Key Findings
- Epidemiology Populations
- Disease Definition
- Methods
- Sources Used for Diagnosed Incidence of ARDS
- Sources Used for Drug-Treatable Incident Cases of Acute Respiratory Distress Syndrome in the Major Pharmaceutical Markets, 2016-2026
- Drug-Treatable Incident Cases of Acute Respiratory Distress Syndrome in the Major Pharmaceutical Markets, 2016-2026
- Disease Definition
- Methods
- Sources Used for Severity of Acute Respiratory Distress Syndrome
- Severity of Acute Respiratory Distress Syndrome, 2016-2026
- Key Findings
- Current Treatment Overview
- Key Findings
- Expert Insight
- Diagnosis
- Treatment Providers and Referral Patterns
- Expert Insight: Diagnosis of Acute Respiratory Distress Syndrome
- Treatment Goals
- Key End Points Used in Clinical Trials for Acute Respiratory Distress Syndrome
- Physician Insights on Clinical End Points
- Expert Insight: Clinical End Points
- Key Current Therapies
- Overview
- Market Events Impacting the Use of Key Current Therapies in Acute Respiratory Distress Syndrome
- Advantages and Disadvantages of Noninvasive Mechanical Ventilation
- Expert Insight: Non-Invasive Mechanical Ventilation
- Advantages and Disadvantages of Invasive Mechanical Ventilation
- Expert Insight: Invasive Mechanical Ventilation
- Advantages and Disadvantages of Nonpharmacological Rescue Therapies for Acute Respiratory Distress Syndrome
- Ongoing Clinical Development
- Expert Insight: Nonpharmacological Rescue Therapies for ARDS
- Advantages and Disadvantages of Corticosteroids
- Expert Insight: Corticosteroids
- Medical Practice
- Overview
- Acute Respiratory Distress Syndrome Treatment Guidelines
- Generalized Treatment Decision Tree for Acute Respiratory Distress Syndrome
- Key Findings
- Etiology and Pathophysiology
- Key Findings
- Expert Insight
- Disease Overview
- Etiology of Acute Respiratory Distress Syndrome
- Risk Factors Associated with Acute Respiratory Distress Syndrome
- Pathophysiology of Acute Respiratory Distress Syndrome
- Disease Definition and Classification of Acute Respiratory Distress Syndrome
- Classification of Acute Respiratory Distress Syndrome Severity
- Clinical Presentation, Symptomatology, and Complications of Acute Respiratory Distress Syndrome
- Complications Associated with Acute Respiratory Distress Syndrome
- Key Pathways and Drug Targets
- Key Findings
- Unmet Need Overview
- Key Findings
- Expert Insight
- Attainment of Unmet Needs
- Current Attainment of Unmet Needs in Acute Respiratory Distress Syndrome
- Future Attainment of Unmet Needs in Acute Respiratory Distress Syndrome
- Top Unmet Needs in Acute Respiratory Distress Syndrome: Current and Future Attainment
- Key Findings
- Emerging Therapies Overview
- Key Findings
- Expert Insight
- Pipeline Trends for Acute Respiratory Distress Syndrome
- Key Emerging Therapies
- Notable Developments Among Key Emerging Therapies for Acute Respiratory Distress Syndrome
- Estimated Launch Dates of Key Emerging Therapies for the Treatment of Acute Respiratory Distress Syndrome
- Key Results from Select Clinical Trials Investigating Solnatide for the Treatment of Acute Respiratory Distress Syndrome
- Key Ongoing Clinical Trials of Solnatide in the Treatment of Acute Respiratory Distress Syndrome
- Expert Insight: Solnatide
- Expectations for Launch and Sales Opportunity of Solnatide in ARDS
- Early-Phase Pipeline Analysis
- Notable Developments in the Early-Phase Pipeline for ARDS
- Select Phase II Compounds in Development for ARDS
- Select Phase I and Preclinical Development Programs for ARDS
- Expert Insight: Early-Phase Pipeline in ARDS
- Key Discontinuations and Failures in Acute Respiratory Distress Syndrome
- Key Discontinuations and Failures
- Expert Insight: Key Discontinuations and Failures
- Patient Registries
- Patient Registries for Acute Respiratory Distress Syndrome
- Prominent Acute Respiratory Distress Syndrome Patient Organizations
- Orphan Drug Designation
- Key Findings
- Access & Reimbursement Overview
- Region-Specific Reimbursement Practices
- Key Market Access Considerations in Acute Respiratory Distress Syndrome: United States
- General Reimbursement Environment: United States
- Key Market Access Considerations in Acute Respiratory Distress Syndrome: EU5
- General Reimbursement Environment: EU5
- Region-Specific Reimbursement Practices
- Appendix
- Key Abbreviations Related to Acute Respiratory Distress Syndrome
- Acute Respiratory Distress Syndrome Bibliography
- Executive Summary
Akash Saini, M.Sc., Ph.D., is the manager of the China In-Depth team at Clarivate. In this role, he leads the efforts to create syndicated landscape and forecast content on various therapy areas for the Chinese market. Previously, he was an assistant manager at BioXcel, where he led consulting projects based on in-silico drug discovery and identification of drug repurposing and in-licensing opportunities. Dr. Saini received his Ph.D. in biochemistry and biotechnology from the International Centre for Genetic Engineering and Biotechnology in New Delhi and conducted postdoctoral research at the University of Massachusetts Medical School. He earned his M.Sc. in biotechnology from Jawaharlal Nehru University in India.